European Innovation Council

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

RespiQ is a healthtech company developing portable, non-invasive breath analysis technology that uses emission spectroscopy and artificial intelligence to detect biomarkers in breath for early identification and real-time monitoring of respiratory diseases such as COPD, as well as other conditions like asthma, lung cancer, and infectious diseases. Its device aims to be affordable and user-friendly, democratizing access to advanced diagnostics, while its platform can also identify digestive issues through breath biomarkers and support personalized guidance via an app that analyzes a digital breath print to deliver diet and health insights, enabling individuals to monitor changes and improve health outcomes.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

EyeControl is a medical technology company specializing in innovative communication solutions for healthcare. It develops devices that enable patients, particularly those with limited mobility or speech impairments, to communicate using eye movements. The company's flagship product is an intensive care unit communication device featuring an infrared camera and a connected computer that translates blinks and eye movements into commands.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

iLoF develops an AI-powered digital health platform that accelerates personalized drug discovery. It uses advanced photonics to collect data, building a digital library of biomarkers for studying tailored treatments and making clinical trials more efficient.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Afon Technology specializes in the development of non-invasive blood glucose monitoring devices aimed at benefiting individuals with diabetes. The company’s innovative technology allows for real-time, pain-free tracking of blood glucose levels, offering features such as continuous detection, potential pre-diabetic identification, and alarm alerts for high and low glucose levels. Users can access trend profiles and time-in-range statistics through a user-friendly app compatible with both iOS and Android systems. Additionally, Afon Technology’s device can transform any smartwatch into a glucose monitoring tool, providing fast and accurate measurements, data logging, and personalized health trends. This approach enhances daily management for diabetics, ultimately reducing the risk of diabetes-related complications.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

Avatar Medical is a developer of a virtual reality medical platform that creates 3D patient avatars to assist surgeons in visualizing medical images. By generating interactive representations based on medical data, the platform enables clinicians to accurately and instantly access critical clinical information. This innovative approach not only enhances the understanding of surgical options but also facilitates the training of medical fellows and improves patient engagement. Avatar Medical aims to transform how medical professionals interact with imaging data, ultimately contributing to better surgical outcomes and patient care.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Brainhero offers home-based neurofeedback therapy using EEG technology. It aims to help children manage symptoms of Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) through engaging, app-based brain training.

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Nanordica Medical is an Estonian medical technology company specializing in advanced wound care solutions. The company has developed a patented nanotechnology that combines copper and silver in nanofibers to effectively remove infections and promote healing in chronic wounds. Nanordica Medical has launched a veterinary product, Ravimus Vet, designed for treating animal wounds, while also focusing on a first-in-class wound dressing for challenging human conditions, such as diabetic foot ulcers. Recent clinical trials have demonstrated that their wound dressing outperforms traditional silver ion-based dressings across multiple efficacy parameters, offering a more powerful antibacterial effect that can inactivate a wider range of bacteria, including drug-resistant strains.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Kahun is a healthcare technology company that offers an online medical platform designed to assist physicians in making informed clinical decisions. By cataloging clinical information from peer-reviewed medical literature, Kahun's platform employs artificial intelligence diagnostic engines to extract relevant insights. This approach not only streamlines the clinical intake process but also enhances the transparency and explainability of healthcare decisions. By optimizing physicians' documentation time and overall cognitive load, Kahun aims to improve clinical outcomes and facilitate faster, evidence-based decision-making within healthcare organizations.

Restore Medical develops a device-based therapy for congestive heart failure. Its product, ContraBand, is a catheter-delivered implant in the pulmonary arteries designed to improve patient quality of life and reduce hospital readmission rates.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Oivi is a Norwegian company founded in 2017 and based in Oslo, specializing in the development of an affordable AI-driven camera and platform for the identification of diabetic eye diseases. The company focuses on facilitating retinal screening in primary care settings, thereby promoting awareness and proactive management of diabetic eye health. Oivi's innovative platform employs automated image capture and diagnostic capabilities to monitor eye diseases effectively through teleconsultation. With a multifaceted team possessing extensive expertise in camera and software development, Oivi aims to empower patients to prevent permanent vision loss associated with diabetes.

Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.

Hy2Care BV is a start-up emerging from the University of Twente in the Netherlands, focused on developing innovative treatments for osteoarthritis, a condition that affects over 100 million individuals in the Western world. The company's primary product is an injectable hydrogel designed to repair cartilage defects, specifically in the knee. This bioresorbable hydrogel consists of a two-component system made from a mixture of natural polymer conjugates that undergo a mild enzymatic reaction to form a cross-linked structure. Hy2Care aims to provide an effective treatment option for osteoarthritis, addressing a significant unmet medical need and enhancing the quality of life for patients suffering from this debilitating condition.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

InVera Medical specializes in developing innovative medical devices focused on treating chronic venous disease. Their flagship product, BioVena™, offers a less invasive, pain-free solution for varicose veins and venous ulcers, utilizing the body's natural biological response.

Peili Vision Oy is a company based in Helsinki, Finland, specializing in virtual reality technology for neurological rehabilitation. Established in 2015, the company has developed a software platform that empowers therapists to design tailored training environments for various therapeutic disciplines, including speech and language pathology, neuropsychology, and occupational therapy. Peili Vision's innovative approach integrates gamification, data analytics, and remote rehabilitation services, allowing healthcare professionals to engage patients in immersive exercises that adapt to their individual needs. This technology facilitates customizable learning experiences, enabling therapists to monitor progress and provide feedback effectively. Peili Vision serves both private and public healthcare clients and operates an additional office in Oulu, Finland.

Thericon is a medical technology company specializing in multiparametric imaging solutions for surgical procedures. It offers a proprietary system that helps surgeons distinguish various tissue types and identify malignant lesions, enhancing surgical accuracy and aiding in informed treatment decisions.

Dermagnostix is a German company founded in 2020, located in the Freiburg and Munich areas. It specializes in developing innovative dermatology diagnostics aimed at enhancing clinical practice and improving patient experiences. The company offers a molecular diagnostic platform that facilitates rapid and objective diagnostics for skin diseases, particularly in distinguishing between eczema and psoriasis at a molecular level. This technology empowers healthcare professionals to provide better care and treatment options, ultimately improving the lives of patients with dermatological conditions.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Aligned Bio specializes in developing advanced biosensor platforms using patented nanowire production methods. Their sensors are designed for applications such as biomedicine, water purification, public safety, and electronics, offering high sensitivity, accuracy, and speed.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Filterlex Medical is a medical device company focused on cardiovascular embolic protection. It develops embolic protection devices to reduce the risk of stroke and other embolic complications during catheter-based structural heart procedures, including transcatheter aortic valve implantation. Its CAPTIS full-body embolic protection device is designed for intuitive deployment and retrieval and is compatible with multiple catheter sizes, enabling integration into existing workflows. The company aims to improve patient safety during minimally invasive heart valve replacement procedures. It was founded in 2015 and is based in Yokneam, Israel.

Xsensio is a digital health company focused on revolutionizing healthcare monitoring. It specializes in developing a wearable, Lab-on-Skin© platform that continuously analyzes biochemical data from the skin's surface in real-time, offering unprecedented insights into health and wellness.

Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Aligned Bio specializes in developing advanced biosensor platforms using patented nanowire production methods. Their sensors are designed for applications such as biomedicine, water purification, public safety, and electronics, offering high sensitivity, accuracy, and speed.

Intelligent Implants is a bioelectronics company developing an implantable electrical stimulation platform that uses wireless devices to stimulate, steer, and monitor bone growth and tissue recovery. The company designs electrotherapeutic medical devices intended to treat diseases and accelerate healing in bone and other tissues. Its implants enable healthcare providers to control and monitor treatment, supporting decision making in patient care. By integrating data, engineering and medicine, Intelligent Implants aims to bring active, connected medical devices to clinical practice, improving outcomes for individuals with bone conditions and related injuries.

enGenome is a bioinformatics company that provides accurate omics-based reports to physicians. Its platform automates variant interpretation guidelines, reducing the number of variants of uncertain significance (VUS) and enabling geneticists to detect pathogenic genomic variants with accuracy and speed. This improves diagnosis and treatment processes for patients with genetic diseases.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Amadix develops cancer diagnostics with a focus on non-invasive screening and early detection. It aims to detect tumors years before symptoms and provide screening signatures in blood to address unmet needs in oncology. Its most advanced product, Colofast, is a blood-based signature for colorectal cancer and advanced adenoma screening, designed to reduce mortality from colon cancer by enabling early intervention. The company pursues analytical validation and demonstration of clinical validity and utility through international multicentre studies, with plans for worldwide commercialization. The leadership combines experience in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property, and independent board members provide guidance on strategy, commercialization, and business development in Europe and the US.

Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.

Operator of a medical technology company intended to offer affordable EEG (electroencephalogram) scans and interpretations for epilepsy patients. The company provides an affordable, Bluetooth-enabled electrode cap to access and interpret medical information from the brain which is uploaded to the cloud, and offers remote diagnosis by neurologists, enabling patients in low- and middle-income countries to get diagnosed and treated for epilepsy.

PKvitality is a French bio-wearable company founded in 2017. It specializes in developing non-invasive health monitoring devices, notably the K’Watch Glucose, a smartwatch that enables diabetic patients to monitor their glucose levels painlessly and discreetly.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease and asthma. The company has created a nanosensor-based wearable device that enables the early detection of subtle changes in a patient's respiratory condition. By identifying these changes before they reach critical stages, NanoVation aims to improve patient outcomes through timely interventions and reduce the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation focuses on empowering healthcare professionals with the tools needed to monitor patients at home effectively, facilitating proactive measures in respiratory care.

GlucoModicum develops non-invasive glucose monitoring technology to enable continuous glucose measurement without needles. Its platform uses magnetohydrodynamic technology to sample interstitial fluid through the skin, providing rapid, gentle glucose monitoring for individuals with diabetes and healthcare providers to manage blood glucose with less discomfort than traditional finger-prick methods.

RadonTec GmbH, founded in 2017 and located in Wittislingen, Bayern, specializes in radon detection and control system solutions aimed at ensuring radon-safe construction. The company develops a comprehensive Radon Detection and Control System (RDC) that employs advanced sensor technology to actively manage ventilation systems and fans. In addition to its primary offerings, RadonTec provides a range of services, including workplace and interior radon measurement, control measurements, and assessments of building materials. This enables customers to obtain reliable radiation measurement devices and accessories tailored for both home and professional applications, promoting safety in environments affected by radon exposure.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.

Intelligent Implants is a bioelectronics company developing an implantable electrical stimulation platform that uses wireless devices to stimulate, steer, and monitor bone growth and tissue recovery. The company designs electrotherapeutic medical devices intended to treat diseases and accelerate healing in bone and other tissues. Its implants enable healthcare providers to control and monitor treatment, supporting decision making in patient care. By integrating data, engineering and medicine, Intelligent Implants aims to bring active, connected medical devices to clinical practice, improving outcomes for individuals with bone conditions and related injuries.

GlucoModicum develops non-invasive glucose monitoring technology to enable continuous glucose measurement without needles. Its platform uses magnetohydrodynamic technology to sample interstitial fluid through the skin, providing rapid, gentle glucose monitoring for individuals with diabetes and healthcare providers to manage blood glucose with less discomfort than traditional finger-prick methods.

ADVITOS GmbH is a Munich-based company that specializes in the design, development, and marketing of extracorporeal multiple organ support therapy products for hospitals in Germany. Founded in 2004, the company offers an innovative treatment method known as ADVanced organ support, which utilizes albumin dialysis to facilitate the removal of various toxins from the liver, lungs, and kidneys. This method enables the elimination of CO2, hepatic toxins, and both water-soluble and protein-bound nephrotoxins, while also addressing metabolic and respiratory acidosis. The ADVOS system operates using standard dialysis accesses and flow rates, distinguishing itself by not requiring gas exchangers for CO2 removal.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

Smart4Diagnostics GmbH, founded in 2018 and based in Munich, Germany, specializes in the manufacturing of digital data fingerprints for human blood samples. The company has developed a device designed for precise measurement and analysis of blood samples, contributing to advancements in medical diagnostics. By focusing on innovative solutions in the healthcare sector, Smart4Diagnostics aims to enhance the accuracy and efficiency of blood analysis, thereby improving patient outcomes.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

KinePict develops medical imaging technology that enhances image quality in interventional radiology while reducing contrast agent and radiation exposure. Its proprietary technologies include Digital Variance Angiography, ultrafast cubic spline-fit algorithms, and real-time non-rigid motion correction, enabling safer procedures, more accurate diagnostics, and improved patient outcomes.

KinePict develops medical imaging technology that enhances image quality in interventional radiology while reducing contrast agent and radiation exposure. Its proprietary technologies include Digital Variance Angiography, ultrafast cubic spline-fit algorithms, and real-time non-rigid motion correction, enabling safer procedures, more accurate diagnostics, and improved patient outcomes.

EyeControl is a medical technology company specializing in innovative communication solutions for healthcare. It develops devices that enable patients, particularly those with limited mobility or speech impairments, to communicate using eye movements. The company's flagship product is an intensive care unit communication device featuring an infrared camera and a connected computer that translates blinks and eye movements into commands.

EyeControl is a medical technology company specializing in innovative communication solutions for healthcare. It develops devices that enable patients, particularly those with limited mobility or speech impairments, to communicate using eye movements. The company's flagship product is an intensive care unit communication device featuring an infrared camera and a connected computer that translates blinks and eye movements into commands.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Positrigo AG is a Zurich-based company specializing in the development, manufacturing, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on providing functional imaging solutions that facilitate the early detection of neurodegenerative diseases, particularly Alzheimer's disease, as well as other conditions like Lewy body dementia, vascular dementia, and frontotemporal dementia. The company's PET scanners are designed to be accessible and affordable, enabling healthcare professionals to diagnose and monitor treatment effectively, while also contributing to the advancement of new therapies in the field of neurology.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

SiriusXT Limited is a company that specializes in the development and manufacturing of soft x-ray microscopes, specifically the SXT system. Founded in 2015 and headquartered in Dublin, Ireland, SiriusXT's innovative technology utilizes a vacuum-based laser-produced plasma light source to enable high-resolution imaging of biological samples. The SXT system is designed for researchers in disease research and drug discovery, providing a crucial tool for visualizing the 3D internal structures of cells in their native, fully hydrated state without the need for stains or contrast agents. This capability is essential for understanding disease pathways, protein-drug interactions, and bio-engineering processes. SiriusXT is recognized for offering the world's first high-throughput, benchtop soft x-ray tomography system, allowing users to produce detailed tomographs quickly and efficiently.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in developing biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Sensocure is a medical technology company specializing in the development and delivery of sensors for healthcare applications. Its flagship product, IscAlert™, is a patented, body-implantable micro biosensor designed to monitor blood flow in human organs. This innovative technology enables real-time monitoring of body functions and early detection of organ damage, with applications in various surgical procedures such as cardiac, vascular, transplant, and reconstructive surgeries. Sensocure aims to address the significant need for early diagnostics in conditions related to insufficient blood supply to vital organs, which is a leading cause of death in the Western world. The company's first sensor version is CE marked and FDA approved.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.